TARGET AUDIENCE
This activity is intended for physicians (hematologists), nurse practitioners, physician assistants, nurses managing patients with hemophilia, and scientists with an interest in basic, translational, and clinical research in hemophilia around the world.

PROGRAM OVERVIEW
With the expected approval of the first gene therapy for hemophilia in the next few months, it is important that clinicians are prepared for implementation in their respective hemophilia treatment centers (HTCs). During this 90-minute session, Drs. Steven Pipe and Guy Young will provide an overview of gene therapy for treatment of hemophilia along with an update on clinical trials in hemophilia A and B. They will also discuss what success looks like and how HTCs should be preparing for the advent of gene therapy. The presentation will conclude with a live question and answer session between attendees and Drs. Pipe and Young.

Unless otherwise noted, ISTH and The France Foundation, the sponsors of this industry-sponsored educational symposium, are solely responsible for its content, including any information presented or distributed during the event.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The France Foundation and ISTH. The France Foundation is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Physicians: The France Foundation designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
This activity is supported by educational grants from BioMarin, Freeline Therapeutics Limited, Pfizer Inc, Shire, Spark Therapeutics, and uniQure, Inc.